Company

Leadership Team

Landos Management Team: Landos has assembled a committed leadership team to finalize the BT-11 preclinical plan, file IND, and execute clinical development, late-phase development and commercialization.

Josep Bassaganya-Riera, DVM, PhD, President and CEO
18 years of business development and fundraising experience in leading biotech companies. Developed innovative large-scale $67M non-dilutive and new equity-based transactions to support translational programs with focus on modeling- and informatics-enabled identification and development of immune modulators, and development of novel IBD therapeutics.

Raquel Hontecillas, DVM, PhD, Chief Scientific Officer (CSO)
18 years of translational research experience in the biotech industry focusing on infectious, immune-mediated, and metabolic diseases. Identified and validated the role of LANCL2 as a therapeutic target for diabetes and IBD. Managing a $56M translational research program in mucosal immunology centered on development of novel IBD therapeutics

Lee Sandstead, Operations, Marketing and Communications Manager
20 years of experience in collaborating with cross-functional teams – from operations, HR, accounting, creative, IT, regulatory, social media, and production to product marketing and legal – to produce effective promotional materials.

Dr. Andrew Leber, Scientific Director
Dr. Leber holds degrees from Penn State University and Virginia Tech in Bioengineering and Genetics, Bioinformatics and Computational Biology. His expertise spans immunology and drug development for autoimmune disease with a focus on immunometabolism. He has ample experience in assessing the therapeutic potential of lead immunoregulatory targets, preclinical and clinical development of drugs for Crohn’s disease and ulcerative colitis.

Chris Garabedian, Senior Business Advisor
Currently Chairman and CEO of Xontogeny, a company focused on the management of early stage life sciences companies from preclinical to clinical proof-of-concept. Helped advance a new drug to market when he was the CEO of Sarepta a $2B publicly traded company.

Clinical Advisory Board - IBD

Landos Clinical Advisory Board - IBD: Landos has also assembled a Clinical Advisory Board for IBD (SAB-IBD) that helps advance BT-11 towards IND approval and to clinical trials, NDA, and commercialization.

Francisco Sylvester, MD (Crohn’s disease Clinical Trials): Over 30 years of experience in Pediatrics for IBD and active research interest in chronic inflammatory disease of the digestive tract and mucosal immunology. Dr. Sylvester has served as the director of CCFA’s PROKIIDS since 2013; he is in his third term as a member of the CCFA Board of Trustees.

Fabio Cominelli, MD Ph.D. (Crohn’s disease Clinical Trials): Over 20 years of experience with human clinical trials for new IBD therapeutics. He serves as the Director of the UH Case Medical Center.

William J. Sandborn, MD (Preclinical and Clinical Gastroenterology): Over 25 years of experience with IBD. He serves as the Director of IBD Center at UCSD, where he supervises a multi-investigator team of physicians, research fellows, nurses, and study coordinators. He managed Phase III clinical testing for the latest Pfizer IBD drugs.

Jean-Frederic Colombel, Ph.D. (Preclinical and Clinical Gastroenterology): Over 20 years of experience in comprehensive research fully dedicated to Crohn’s disease and ulcerative colitis. He currently serves as the Director of the Helmsley IBD Center, Mount Sinai, New York City and as Chair of the International Organization of IBD (IOIBD).

Board of Directors

Josep Bassaganya-Riera, Chairman of the Board
18 years of business development and fundraising experience in leading biotech companies. Developed innovative large-scale $67M non-dilutive and new equity-based transactions to support translational programs with focus on modeling- and informatics-enabled identification and development of immune modulators, and development of novel IBD therapeutics.

Chris Garabedian, Senior Business Advisor
Currently Chairman and CEO of Xontogeny, a company focused on the management of early stage life sciences companies from preclinical to clinical proof-of-concept. Helped advance a new drug to market when he was the CEO of Sarepta a $2B publicly traded company.